1 High-Flying Stock With More Upside Ahead

Over the past 5 years, Axsome Therapeutics (NASDAQ: AXSM) has been connected fire. The institution has crushed the marketplace successful this play connected the backmost of coagulated objective and regulatory progress. At this point, it's just to inquire whether determination is immoderate upside near for the company, which is connected the verge of reaching large-cap status.

The bully quality is that determination mightiness conscionable be. Let's sermon wherefore it's not excessively precocious to put successful Axsome Therapeutics.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

Axsome's existent lineup features Auvelity, a medicine approved for depression; Sunosi, which treats daytime sleepiness associated with narcolepsy; and Symbravo, a migraine medicine. The company's apical enactment is increasing astatine a bully clip. In the 3rd quarter, Axsome's gross came successful astatine $171 million, up 63% compared to the year-ago period.

Symbravo was conscionable approved successful January 2025, portion adjacent Auvelity hasn't been connected the marketplace for that agelong -- it earned the greenish airy successful August 2022. So, these medicines should inactive thrust top-line maturation for a agelong clip earlier moving into patent cliffs.

Axsome Therapeutics tin summation gross by securing caller approvals and statement expansions. Let's archetypal see the latter. The institution is seeking a caller denotation for Auvelity successful Alzheimer's illness (AD) agitation. The medicine performed good successful signifier 3 studies and is presently being considered by the U.S. Food and Drug Administration (FDA) for this imaginable statement expansion.

Elsewhere, Sunosi completed a signifier 3 survey successful adults with ADHD. Axsome Therapeutics plans to tally respective different late-stage objective trials for this drug, including successful slump with daytime sleepiness; it should yet prosecute these markets arsenic well.

The institution is moving connected respective different products that could gain support wrong the adjacent fewer years. For instance, AXS-12 is being investigated to dainty cataplexy successful narcolepsy patients, portion AXS-14 could, eventually, gain the greenish airy successful fibromyalgia. Axsome Therapeutics estimates that these caller products and statement expansions could adhd billions to its income potential.

Consider the company's enactment successful AD with Auvelity. Even though determination are implicit 5 cardinal patients successful the U.S. who endure from AD agitation, determination is lone 1 FDA-approved medicine successful this market. There is simply a immense addressable marketplace present for Axsome Therapeutics, and that's conscionable a azygous indication.